The largest cannabis study ever conducted found no evidence it helps anxiety, depression, or PTSD and warned it may be making all three worse - thesciverse

Search →

AstronomyGeneticsMedical Research & InnovationsNeurosciencePsychologyScience news

All

Astronomy

Genetics

Medical Research & Innovations

Neuroscience

Psychology

Science news

Medical Research & Innovations

The largest cannabis study ever conducted found no evidence it helps anxiety, depression, or PTSD and warned it may be making all three worse

Darlene M. Alexander<br>Science journalist

Medical Research & Innovations<br>7 min read<br>·The Lancet

About 27 percent of people aged 16 to 65 in the United States and Canada have used cannabis for medical purposes, with about half using it to manage their mental health. Anxiety. Depression. PTSD. These are the three conditions that drive the majority of medicinal cannabis prescriptions across North America, Australia, and Europe. They are also the three conditions for which the largest review of medicinal cannabis ever conducted just found no evidence that it works.

The study, published in The Lancet Psychiatry on March 17, 2026, was led by Dr. Jack Wilson at the University of Sydney’s Matilda Centre. It analyzed 54 randomized controlled trials spanning 45 years. Not a small sample. Not a narrow methodology. The most comprehensive assembly of clinical evidence on this question that has ever been put together. And after pooling and analyzing it all, the conclusion was the same across every primary mental health indication driving the market: no evidence of effectiveness.

What the Review Actually Examined

The scope of the Wilson review matters for understanding what its findings do and do not establish. The analysis examined both the safety and effectiveness of cannabinoids across a wide range of mental health conditions, including anxiety disorders, major depressive disorder, PTSD, psychotic disorders, attention deficit hyperactivity disorder, autism spectrum disorder, sleep disorders, and several substance use disorders. The cannabinoid products studied included both CBD and THC products, covering the full range of preparations currently prescribed in legal medicinal cannabis markets.

The systematic review and meta-analysis methodology, which pools the results of multiple randomized controlled trials to identify patterns across a larger combined dataset than any individual study can provide, represents the highest level of evidence available in clinical medicine. A single clinical trial can be affected by sample size, population selection, dosing protocols, and statistical chance. A meta-analysis of 54 randomized controlled trials across 45 years is not vulnerable to those individual limitations in the same way.

What it found for anxiety, depression, and PTSD was not weak evidence. It was an absence of evidence. The clinical trials conducted over four and a half decades, using the full range of cannabinoid preparations available, across diverse patient populations and study designs, did not produce a reliable signal of therapeutic benefit for the three conditions that now justify the majority of prescriptions.

The Gap Between Experience and Evidence

The finding will feel wrong to a significant number of people who use cannabis for anxiety or depression and experience relief. That subjective experience is real and deserves honest engagement rather than dismissal. But understanding what the clinical trial evidence is and is not measuring helps clarify why the gap exists.

Cannabis produces immediate pharmacological effects that many people describe as calming, distracting, or mood-lifting. These short-term effects are real. What randomized controlled trials measure is whether those effects translate into clinically meaningful, sustained improvements in the underlying condition over time, compared to a placebo control that accounts for the significant therapeutic effect of believing you have received an active treatment.

The anxiety and depression that patients report managing with cannabis tends to return between uses. The studies that have tracked symptom trajectories over time have consistently failed to show that cannabinoid treatment produces the durable reduction in disorder severity that defines a clinically effective intervention. The experience of relief is genuine. The relief is not treating the disorder in the way that clinical effectiveness requires it to be treated.

There is also a second possibility that the Wilson review authors raised directly. "The routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments," Wilson said. People using cannabis as their primary management strategy for anxiety, depression, or PTSD may be displacing access to treatments for which clinical evidence does exist, while...